Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.62 CAD | 0.00% | +5.19% | -9.50% |
11/04 | Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA | CI |
11/04 | Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.50% | 89.03M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA